Merck at IDWeek 2026
Oct 21–24, 2026 Washington, DC ~12k attendees Website
Merck brings 23 presentations to IDWeek 2026 in Washington, and exhibits at Booth 605, 705, BS 26, BS 27. Its program centres on RSV protection for infants with the antibody clesrovimab, pneumococcal disease and vaccination in adults, and new HIV treatment and prevention options. One concrete thread reports a weekly islatravir and ulonivirine regimen that kept HIV suppressed after switching.
| Organization | IDWeek 2026 Attendance |
|---|---|
Merck Rahway, NJ | |
Global biopharmaceutical company, called MSD outside the US and Canada, that develops medicines and vaccines for people and animals. | Booth Exhibiting at Booth 605, 705, BS 26, BS 27 Thu, Oct 2210am–2pmFri, Oct 2310am–2pmSat, Oct 2410am–2pm Poster Thu Oct 22 12:15pm–1:30pm Clesrovimab safety and exposure levels in infants under 2 kilograms: A subgroup analysis of the phase 3 SMART study Poster Thu Oct 22 12:15pm–1:30pm Clinical and Economic Burden of Infection Related to Carbapenem-resistant Pathogens in Taiwan Poster Thu Oct 22 12:15pm–1:30pm Impact of Antidrug Antibodies on the Pharmacokinetics, RSV Serum-Neutralizing Activity, and Safety of Clesrovimab in a Phase 3 Trial (SMART) Poster Thu Oct 22 12:15pm–1:30pm Impact of Clesrovimab on Commercially Available RSV Rapid Antigen Based Diagnostic Assays Poster Thu Oct 22 12:15pm–1:30pm RSV Coinfection With Community Respiratory Pathogens Following Administration of Clesrovimab in the Phase 3 SMART Trial Poster Thu Oct 22 12:15pm–1:30pm RSV Incidence Rates in RSV Season 2 of the Phase 3 SMART Trial of Clesrovimab: Impacts of Participant Population and RSV Circulation Talk Thu Oct 22 12:20pm–12:25pm RSV Incidence Rates in RSV Season 2 of the Phase 3 SMART Trial of Clesrovimab: Impacts of Participant Population and RSV Circulation Respiratory infections and COVID-19Vaccines Industry Fri Oct 23 7:00am–8:00am Help Protect Infants From RSV Lower Respiratory Tract Disease in Their First RSV Season Respiratory infections and COVID-19Vaccines Industry Fri Oct 23 8:00am–9:00am Recognizing and Addressing Risks of Shifting Epidemiology of Pneumococcal Disease in Adults 50+ VaccinesRespiratory infections and COVID-19 Industry Fri Oct 23 11:15am–12:00pm Exploring a Switch Regimen for Appropriate Adults Living With HIV-1 HIV, sexually transmitted infections and viral hepatitisAntimicrobials, resistance and stewardship Poster Fri Oct 23 12:15pm–1:30pm Exploring Preferences and Adherence & Persistence among Individuals Initiating PrEP in Portugal: the POSITIVE CARE Study Poster Fri Oct 23 12:15pm–1:30pm Exposure-Response Analysis of Islatravir 0.25 mg With Doravirine 100 mg Once Daily in Treatment-Naive and Virologically Suppressed People Living With HIV-1 at Week 48 Poster Fri Oct 23 12:15pm–1:30pm Potential Drug-Drug Interactions in People Living With HIV on Antiretroviral Therapy Stratified by Age and Sex Poster Fri Oct 23 12:15pm–1:30pm Switching to Islatravir + Ulonivirine Once Weekly Maintained HIV-1 Viral Suppression at Week 24 in the Presence of Baseline NNRTI Resistance-Associated Mutations and M184I/V in Proviral DNA Talk Sat Oct 24 11:30am–11:43am Phase 1 Study to Evaluate the Absorption, Metabolism, and Excretion of MK-8527, a Nucleoside Reverse Transcriptase Translocation Inhibitor, in Adults Without HIV HIV, sexually transmitted infections and viral hepatitis Poster Sat Oct 24 12:15pm–1:30pm A Comparative Analysis of HIV Transmission Model Structure with Matched Survey-Derived Contact-Rate Inputs: Policy Implications Under Economic and Resource Trade-offs Poster Sat Oct 24 12:15pm–1:30pm Anti Drug Antibody Responses to Clesrovimab Are Driven by Natural RSV Exposure Following Declining Protective Antibody Levels and Are Mitigated by Second-Season Dosing Poster Sat Oct 24 12:15pm–1:30pm Barriers to PrEP, HIV knowledge and perceived stigma among MSM and Heterosexual People Living with HIV in Portugal: The POSITIVE CARE Study Poster Sat Oct 24 12:15pm–1:30pm Comparisons of Population Effects of Pneumococcal Vaccination Programs in the United States and Canada — Considerations for Future Immunization Policy Poster Sat Oct 24 12:15pm–1:30pm Disease Severity and Serotype Distribution of PCV15-Type Non-Bacteremic Pneumococcal Pneumonia Among Hospitalized Adults in Taiwan Poster Sat Oct 24 12:15pm–1:30pm Population-Level Effects of Pneumococcal Conjugate Vaccines on Pneumococcal Disease in Europe: A Targeted Literature Review Poster Sat Oct 24 12:15pm–1:30pm Safety and Immunogenicity of V116, an Adult-specific Pneumococcal Conjugate Vaccine, in Pneumococcal Vaccine-Naïve Adults ≥50 Years of Age: Post-hoc Analysis of Phase 3 Data in the Overall and East Asian Populations Poster Sat Oct 24 12:15pm–1:30pm Social Determinants of Adult Vaccination in the United States (US): An Analysis of the National Health Interview Survey (NHIS) |
Instantly find 20 buyers from Merck
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by IDWeek, the Infectious Diseases Society of America (IDSA) or its partner societies (SHEA, HIVMA, PIDS and SIDP). Submit a correction